Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.42 |
| ▸ | CDK2 | P24941 | 15/20 | 0.42 |
| ▸ | GSK3B | P49841 | 11/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30519023 | 0.93 | EPHX1 (0.56) | EPHX1BCHECCNE1CDK2GSK3B | |
| SCHEMBL25945724 | 0.82 | BCHE (0.43) | EPHX1BCHECCNE1CDK2GSK3B | |
| SCHEMBL31629846 | 0.82 | BCHE (0.43) | EPHX1BCHECCNE1CDK2GSK3B | |
| SCHEMBL3695150 | 0.80 | EPHX1 (0.40) | EPHX1BCHECCNE1CDK2GSK3B | |
| SCHEMBL14501550 | 0.79 | EPHX1 (0.47) | EPHX1CCNE1CDK2GSK3B | |
| SCHEMBL31512370 | 0.77 | EPHX1 (0.50) | EPHX1CCNE1CDK2GSK3B | |
| SCHEMBL18265725 | 0.76 | EPHX1 (0.46) | EPHX1BCHECCNE1CDK2GSK3B | |
| SCHEMBL24280139 | 0.76 | SMN1; SMN2 (0.41) | EPHX1BCHECCNE1CDK2 | |
| SCHEMBL3896933 | 0.75 | MMP1 (0.47) | EPHX1MMP1MMP2MMP3GAA | |
| SCHEMBL2576177 | 0.75 | ALDH1A1 (0.47) | EPHX1BCHECCNE1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | DICE ALPHA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | IL17A, IL23R, IL18 | EPHX1 2249/4885BCHE 4672/4885CCNE1 1767/4885 |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | IL17A, IL2, IL36G | EPHX1 2501/4885BCHE 4862/4885CCNE1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.